TMIC-33. POTENTIAL OF MAGNETIC HYPERTHERMIA TO STIMULATE AN IMMUNE RESPONSE IN GLIOBLASTOMA

INTRODUCTION Glioblastoma, the most common primary adult brain malignancy, is an aggressive tumour with a median survival of around one year. Despite decades of research there has been minimal improvement in prognosis and innovative new treatments are urgently required. We aimed to focus on the tumour microenvironment (TME) and designed a novel therapeutic approach, using nanotechnology to achieve in-situ tumour vaccination mediated by localised hyperthermia, in combination with immune checkpoint inhibition.